

Investigator	Abstract #	Abstract Title	Medium	Session	Investigator's Site
Ian Flinn	67	Rapcabtagene Autoleucl (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update	Oral	628	Tennessee Oncology
Ian Flinn	459	A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma	Oral	624	Tennessee Oncology
Ian Flinn	1646	Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma	Poster	623	Tennessee Oncology
Ian Flinn	3008	Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study	Poster	623	Tennessee Oncology
Ian Flinn	3255	Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study	Poster	642	Tennessee Oncology
Ian Flinn	4388	Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucl (Brexu-cel) in ZUMA-2 Cohorts 1 and 2	Poster	623	Tennessee Oncology
Ian Flinn	4632	Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies	Poster	642	Tennessee Oncology
Jesús Berdeja	495	Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestic-2 Cohort a and Trimm-2 Studies	Oral	654	Tennessee Oncology
Jesús Berdeja	594	Pharmacodynamic Signatures and Correlatives of Response in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Talquetamab or Teclistamab Plus Daratumumab and Pomalidomide	Oral	651	Tennessee Oncology
Jesús Berdeja	900	Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients	Oral	653	Tennessee Oncology
Jesús Berdeja	922	Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein - Coupled Receptor Class C Group 5 Member D (GPRC5D) -Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)	Oral	704	Tennessee Oncology
Jesús Berdeja	1982	Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)	Poster	654	Tennessee Oncology

Jesús Berdeja	2069	BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results	Poster	704	Tennessee Oncology
Jesús Berdeja	2080	Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease	Poster	704	Tennessee Oncology
Jesús Berdeja	3357	Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study	Poster	654	Tennessee Oncology
Jesús Berdeja	3366	Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degradar, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma	Poster	654	Tennessee Oncology
Jesús Berdeja	3370	First Results from the Dose Escalation Part of the Phase 1 Study of KTX1001, an Oral, First-in-Class, Potent Inhibitor of MMSET/NSD2 for Relapsed/Refractory Multiple Myeloma (RRMM)	Poster	654	Tennessee Oncology
Jesús Berdeja	3388	Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMma-2 Cohort 2c Extended Follow-up	Poster	655	Tennessee Oncology
Jesús Berdeja	4653	Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestic-2 and Monumental-2 Studies	Poster	651	Tennessee Oncology
Jesús Berdeja	4732	Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received >1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study	Poster	654	Tennessee Oncology
William Donnellan	1514	Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib	Poster	617	Tennessee Oncology
William Donnellan	4600	Olutasidenib Alone or in Combination with Azacitidine in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data	Poster	637	Tennessee Oncology
Richard Zuniga	1739	Safety and Efficacy in Patients with Advanced Lymphomas from a Global	Poster	627	New York Cancer & Blood Specialists

		Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC			
Richard Zuniga	3136	Clinical and Molecular Characterization of Disease Progression in Patients (Pts) with Low-Risk Myelofibrosis (MF) Enrolled in the MOST Study	Poster	631	New York Cancer & Blood Specialists
Erin Pettijohn	675	Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups	Oral	654	The Cancer and Hematology Centers (Michigan)
Erin Pettijohn	2258	Starting a Blood Bank inside a Private Practice	Poster	901	The Cancer and Hematology Centers (Michigan)